CENTURY THERAPEUTICS INC (IPSC)
US15673T1007 - Common Stock
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows:
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based...
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent...
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET.
IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023
IPSC stock results show that Century Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Century Therapeutics (NASDAQ:IPSC) just reported results for the fourth quarter...
Commit To Buy Century Therapeutics At $2.50, Earn 10.1% Annualized Using Options
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile,...
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational biology
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational biology
3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024
While not on everyone’s radar, these enticing entities just might deliver the goods.
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent...
Commit To Purchase Century Therapeutics At $2.50, Earn 57% Annualized Using Options
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
– Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily...
Century Therapeutics stock gains after IND clearance for lupus candidate (NASDAQ:IPSC)
Century Therapeutics receives FDA clearance for its investigational new drug (IND) for CNTY-101 in systemic lupus erythematosus (SLE), leading to an 8%...
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
– Represents second IND clearance for CNTY-101, the Company’s lead iPSC-derived CD19-targeted CAR NK cell product candidate, and first in an autoimmune and...
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent...
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential
Although speculative ideas tend to be losers more so than winners, these 10-bagger penny stocks might tempt the gambler.
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
PHILADELPHIA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent...
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Brent Pfeiffenberger, Pharm.D., MBA, appointed Chief Executive Officer of Century Therapeutics - - Initial data from the ongoing Phase 1 ELiPSE-1 trial...
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
PHILADELPHIA and MADISON, Wis., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology...